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Summary 
The immunogenicity of a chimeric T/B cell peptide corresponding to antigenically characterized 
epitopes of the Chlamydia trachomatis major outer membrane protein (MOMP) was studied in 
mice to further define its potential use in the development  of a subunit vaccine in preventing 
blinding trachoma in humans. The chimeric peptide, designated A8-VDI, corresponds to a conserved 
MOMP T helper (Th) cell epitope(s) (A8, residues 106-130) and serovar A VDI (residues 66-80), 
which contains  the serovar-specific neutralizing epitope ~lVAGLEK76. Mice immunized with 
peptide A8-VDI produced high-titered polyclonal IgG antibodies which recognized the VAGLEK- 
neutralizing epitope. Peptide A8-VDI primed A/J mice to produce high-titered serum-neutralizing 
antibodies in response to a secondary immunization with intact chlamydial elementary bodies 
(EBs). Peptide A8-VDI, but not peptide VDI alone, was immunogenic in six different inbred 
strains of mice disparate at H-2, indicating that the Th call epitope(s) contained in the A8 portion 
of the chimera was recognized in the context of multiple major histocompatibility complex (MHC) 
haplotypes. An unexpected finding of this work was that different inbred strains of mice immunized 
with the chimeric peptide produced antibodies of differing fine spedficities to the VDI portion 
of the chimera. Some mouse strains produced anti-VDI antibodies  that did not recognize the 
VAGLEK-neutralizing epitope. The ability of mice to respond to the VAGLEK-neutralizing site 
was not dependent on MHC haplotype since mouse strains of the same H-2 haplotype produced 
anti-VDI antibodies  of differing fine specificity. 
T 
rachoma, the leading cause of preventable blindness in 
developing nations of the world, is caused by Chlamydia 
trachomatis serovars A, 13, and C. It is estimated that 500 mil- 
lion people suffer from trachoma and as many as 10 million 
of these individuals are permanently blinded by the disease 
(1). Because of its tremendous impact on human health, much 
attention has been focused on the development of a vaccine 
to prevent or control blindness  due to trachoma. 
Vaccines employing whole chlamydial organisms have been 
used in attempts to vaccinate humans against trachoma; how- 
ever, they have failed in part due to host hypersensitivity reac- 
tions produced by the vaccine and the inability of systemic 
immunization to produce sufficient levels of local antibody 
to afford protection (2-4). Protective immunity in experimen- 
tally infected humans and nonhuman primates to ocular rein- 
fection with C. trachomatis is serovar specific (5-7). Further- 
more, resistance  to  ocular reinfection  correlates  with the 
presence of serovar-specific tear antibodies (8, 9), suggesting 
that those chlamydial surface antigens that form the basis for 
serovar-specific immunity are target antigens for the devel- 
opment of a trachoma vaccine. Thus, a strategy for the de- 
velopment of a trachoma vaccine is  to  avoid chlamydial- 
immunopathological responses and focus on vaccination with 
protective  antigen(s). 
The major outer membrane protein (MOMP) 1 of C. tra- 
chomatis accounts for 60% of the outer membrane by weight, 
is surface exposed, and is the primary chlamydial-serotyping 
antigen (10-12). The genes encoding the MOMPs of trachoma 
serovars A, B, and C have  been sequenced (13, 14). The MOMP 
is composed of four variable domains (VDs) that are equally 
interspersed between highly conserved regions. The sequences 
contained within exposed VDs comprise  linear B cell epi- 
topes which are C.  trachomatis-serotyping determiners  and 
primary targets for neutralizing mAbs. Neutralizing mAbs 
specific to the MOMP of trachoma serovars A, C, and B map 
to linear epitopes located in VDs I and II, respectively (13, 
1  Abbreviations  used in this~pen EB, dementary body; MOMP, major outer 
membrane protein; VD, variable domain. 
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tigens for the development  of a synthetic or recombinant 
subunit trachoma vaccine.  In addition to neutralizing B-cell 
epitopes, an effective subunit trachoma vaccine will likely re- 
quire native MOMP T  helper (Th) cell epitopes to provide 
specific T  cell memory and recall  high-titered  neutralizing 
antibodies in vaccinated individuals upon natural reexposure 
to or infection by chlamydiae. 
T  cell antigenic determinants  of C. trachomatis serovar  A 
MOMP have been mapped (16).  A  25-amino acid peptide, 
designated A8, that corresponds to conserved residues 106--130, 
provides cognate Th cell function for the production of anti- 
bodies to serovar A-specific epitopes located in MOMP VDI. 
Mice immunized with a colinearly synthesized peptide cor- 
responding to A8 and VDI sequences, designated A8-VDI, 
produced high-titered antibodies specific to VDI that reacted 
with intact chlamydiae. Because the A8 peptide sequence is 
conserved among  different C.  trachomatis serovars  (13,  14, 
17-21), the Th cell epitope(s) contained within its sequence 
is likely antigenically common. Thus, peptide A8, in combi- 
nation with trachoma serovar A-, B-, and C-neutralizing 
epitopes, may be used as a common carrier for the produc- 
tion of protective antibodies against all three trachoma serovars. 
To more thoroughly define the utility of peptide A8 in 
chlamydial-vaccine development, we have performed additional 
studies to determine: if polyclonal antibodies produced against 
the chimeric peptide are functional-neutralizing  antibodies; 
the ability of peptide A8 to prime Th and B cell immunity in 
response to a secondary immunization with intact chlamydial 
elementary bodies (EBs); and the immunogenicity of the pep- 
tide in mouse strains differing at H-2 to delineate the genetic 
restriction of the Th cell repertoire capable of responding to 
the peptide. 
Our results showed that immunization with peptide A8- 
VDI induced the production of neutralizing antibodies, and 
that  the peptide was able to prime mice to produce excep- 
tionally high titers of serum-neutralizing antibodies after sec- 
ondary immunization with intact chlamydiae. Moreover, the 
A8-VDI peptide was immunogenic in six H-2-disparate in- 
bred strains of mice, suggesting that  the Th cell epitope(s) 
contained within the peptide is recognized by multiple MHC 
alleles. 
Materials and Methods 
Chlaraydiae 
C. trachoraatis  serovar A (strain Hat-13) was grown in HeLa 229 
cells and EBs were purified from infected cells by density gradient 
centrifugation  as previously described (10). 
STathetic Peptides 
Peptides A8, A VDI, and A8-VDI were synthesized on ILapid- 
Amide  resin using  a RAMPS (DuPont Co.,  Wilmington,  DE) 
manual synthesizer or using an automated  synthesizer (430; Ap- 
plied Biosystems Inc., Foster City, CA) as described previously (16). 
Peptide A VDI corresponds to serovar A MOMP residues 63-83 
(GAAIrI'TSDVAGLEKDPVANVA) and contains the linear serovar 
A-specific neutralizing  epitope 71VAGLEK76. Peptide A8 corre- 
sponds  to serovar A  MOMP residues 106-130 (ALNIWDRF- 
DVFCTLGATTGYLKGNS) and contains a functional Th ceU epi- 
tope(s) that provides cognate help for the production of antibodies 
to B cell epitopes contained in VDI (16). Peptide A8-VDI is a 40- 
residue  chimeric  peptide  colinearly  synthesized  with  residues 
106-130 at its NH2 terminus  and residues 66-80 at its COOH 
terminus. 
mAb 
mAb A-20 is specific to C. trachomatis serovar A MOMP and 
maps to a linear epitope in its VDI (13, 22). mAb A-20 binds to 
intact  serovar A  EBs by dot-immunoblot  (22) and  neutralizes 
chlamydial infectivity in vitro (23). 
ELISA 
The ELISA used has been previously described (16). Briefly, mi- 
crotiter  plates (Immulon  2; Dynatech Laboratories, Inc., Alexan- 
dria, VA) were coated overnight at 4oC with 100/A of synthetic 
peptide (5/~g/ml),  purified A MOMP (0.5/~g/ml),  or formalin- 
killed C. trachomatis  serovar A EBs (10/~g/ml) in 0.05 M "Iris buffer 
(pH 7.5) containing 0.15 M NaC1. Serial twofold-dilutions of mouse 
sera were tested in duplicate. Mouse IgG was detected using an 
anti-mouse IgG-alkaline phosphatase conjugate (3' chain specific; 
Zymed Laboratories Inc., San Francisco, CA) followed by substrate 
(5 mg p-nitrophenyl  phosphate in 10 ml of 0.1 M 2:2 amino-2- 
methyl-l:3-propandiol,  pH 10.3). Absorbance at 405 nm was mea- 
sured with an ELISA reader (Bio-Rad Laboratories, Richmond, 
CA). Pooled preimmune or normal mouse sera were used for nega- 
tive controls. ELISA titers were expressed as the highest serum di- 
lution  giving  an absorbance value of 0.30D  units. 
Fine Specificity of Antibody Response 
The peptide--pin-based assay described by Geysen et al. (24, 25) 
was used to determine the fine specificity  of mouse antipeptide sera. 
Sequential and overlapping octapeptides representing the serovar A 
MOMP VDI sequence (61-85) were synthesized on prederivatized 
polyethylene pins, (Epitope Scanning Kit; Cambridge Research Bio- 
chemicals Inc., Wilmington,  DE) as described by the manufacturer. 
Reactivity of mouse IgG antibody to the solid phase octapeptides 
was determined by ELISA using  anti-mouse IgG-alkaline phos- 
phatase conjugate  as described above for peptide ELISAs. 
Neutralization  of Chlam),dial Infectivity 
In vitro neutralization  of chlamydial infectivity by mouse an- 
tisera was assayed on Syrian hamster kidney (HaK) cells grown in 
96-weU microtiter  plates (Linbro,  96 flat-bottomed  wells; Flow 
Laboratories,  Inc.,  McLean, VA). Briefly, 10  s HaK cells were 
grown in 96-well plates 24 h before inoculation.  Purified serovar 
A EBs were diluted in 0.25 M sucrose, 10 mM sodium phosphate, 
5 mM t-glutamic  acid (SPG, pH 7.2) to give a final concentration 
of 4  x  10  s inclusion-forming units (IFUs)/ml.  Twofold dilutions 
of pooled mouse sera were mixed with an equal volume of serovar 
A EBs suspended in SPG buffer. The mixtures were incubated at 
37~  for 1 h and 50 #1 of the mixture was inoculated in triplicate 
onto confluent Hal(cell monolayers. After a 2-h incubation at 37~ 
the inocula were removed, and the monolayers were washed with 
100 #1 of HBSS. Monolayers were refed with 200 #1 of MEM sup- 
plemented with 10% FCS (MEM-10) containing  0.5 #g cyclo- 
heximide/ml  and incubated  at 370C  for 70 h.  The monolayers 
were fixed with methanol and chlamydial inclusions identified by 
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to chlamydial LPS. The calculations for determining  percent re- 
duction of IFUs by mouse antisera were done as previously de- 
scribed (26). 
Immunization  of Mice 
Immunoreactivity and Neutralizing Activity of Anti-AS-VDI Sera. 
A/J mice were immunized (five mice per group) intraperitoneally 
with 50/zg of peptides A8-VDI, VDI, or A8 emulsified in CFA. 
The mice were given two booster immunizations intraperitoneally 
with the same concentration of the three peptide immunogens in 
IFA at 3-wk intervals. Mice were pre-bled and bled again 2 wk 
after the third immunization by tail bleeding. Sera were tested for 
IgG antibody reactive to peptide VDI, MOMP, and intact EBs by 
ELISA, and for functional antibody activity by performing neu- 
tralization assays. The fine specificity  of anti-A8-VDI antisera was 
determined  using  the peptide-pin  assay against  overlapping se- 
quential-octamer peptides corresponding  to the VDI sequence. 
The Ability of Peptide A8-VDI to Function as a Priming Immuno- 
gen for the Generation of an Anamnestic Neutralizing Antibody Re- 
sponse.  A/J mice (five mice per group) were primed with 50/~g 
i.p.  peptide A8-VDI, 3  x  107 IFUs  of serovar A EBs, or PBS 
emulsified in CFA. 5 wk after the primary immunization,  mice 
were injected intraperitoneally with the same concentrations of pep- 
tide A8-VDI, serovar A EBs, or PBS emulsified in IFA. Mice were 
bled 5 wk after the primary immunization and 3 wk after the sec- 
ondary immunization.  The  sera from  individual  mice  in  ex- 
perimental groups were pooled and analyzed by ELISA for IgG 
antibody reactive to peptide VDI and EBs. The neutralizing titers 
of the pooled antipeptide sera were determined as described above. 
Imrnunogenicity of Peptide A8-VDI in Inbred and H-2 Congenic 
Mice.  The following inbred strains of mice were used: A/J (H- 
2~), C57BL/10SnJ  (H-2b), BALB/cByJ (H-2d), CBA/J  (H-2k), 
DBA/1J (H-2q), SJL/J (H-2').  H-2 congenic mouse strains used 
were B10.A/SgSnJ (H-2~), B10.BK/SgSnJ (H-2k), A.BY/SNJ (H- 
2b), and A.SW/SnJ (H-2'). Mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Both sexes of mice at ,,~8-12 wk 
of age were used for experimentation.  Groups of five mice were 
immunized by intraperitoneal injection of 50 #g of A8-VDI or VDI 
alone emulsified in CFA and boosted twice at 3 wk intervals with 
the same dose of peptide in IFA. Mice were bled 2 wk after the 
final immunization. Sera  were collected,  pooled according to groups, 
and tested by ELISA against serovar A VDI, MOMP,  and EBs. 
The fine specificity  of the antibody response to linear determinants 
in the VDI sequence was determined using the peptide-pin assay. 
Results 
Neutralizing  Activity and Molecular Specificity of Antibodies 
Produced by Mice Immunized with Peptide A8-VDL  A/J mice 
immunized with the chimeric peptide A8-VDI produced IgG 
antibodies reactive with the VDI peptide, serovar A MOMP, 
and EBs (Table 1), whereas sera from mice immunized with 
the free peptides A8 or VDI were nonreactive. Furthermore, 
the antibodies produced in response to immunization with 
peptide A8-VDI recognized MOMP in its native configura- 
tion and were neutralizing. 
To define the molecular specificity of the anti-VDI anti- 
bodies, we assayed the reactivity of the antipeptide sera against 
sequential and overlapping octameric peptides corresponding 
to the serovar A MOMP VDI sequence (Fig.  1). Anti-A8- 
VDI sera reacted strongly with six octamer peptides of the 
VDI sequence spanning residues 69-81 (Fig.  1, top). These 
residues contain the 71VAGLEK  76 sequence recognized by the 
serovar A-specific mAb A-20 (Fig. 1, bottom). Thus, the poly- 
donal IgG antibodies produced by immunization of mice with 
peptide A8-VDI recognized the same key serovar A-specific 
epitope as the neutralizing mAb A-20. 
The Ability of Peptide A8-VDI to Function as a Priming Im- 
munogen.  An effective trachoma vaccine will likely depend 
on its ability to prime protective T  and B cell immunity so 
that natural reexposure to or infection by chlamydiae induces 
an anamnestic-immune response to targeted MOMP-neutral- 
izing epitopes. To determine if the peptide A8-VDI could 
function in this capacity, A/J mice were: immunized with 
50/~g intraperitoneally A8-VDI peptide in CFA and then 
boosted 5 wk later with 3  x  107 formalin-killed EBs emul- 
sifted  in IFA;  or primed intraperitoneally 3  x  107 EBs  in 
CFA and boosted with peptide A8-VDI in IFA. Mice were 
bled 5 wk after the primary immunization, and 3 wk after 
the secondary immunization, and sera were tested by ELISA 
for IgG antibodies to peptide VDI and intact EBs. The results 
showed that peptide A8-VDI was an excellent priming im- 
Table  1.  Immunoreactivity and Neutralizing Properties of Anti-A8-VDI Sera 
mAb or mouse antiserum 
ELISA IgG antibody  titer against serovar A 
Neutralizing  titer 
VDI  MOMP  EBs  (NDs0) 
mAb A-20*  32,768  32,768  32,768  512 
Anti-A8-VDI  16,384  16,384  16,384  1,024 
Anti-AVDI  <16  <16  <16  <16 
Anti-A8  <16  <16  <16  <16 
ELISA titers are expressed  as the reciprocal  of pooled serum dilutions giving an absorbance  reading (405 nm) of 0.3. Absorbance  values of preimmune 
or normal mouse sera were 0.1 or less. Neutralization titers are expressed  as the reciprocal  of pooled serum dilutions that reduced  chlamydial  IFUs 
for HaK cells by 50% or more. Preimmune or normal mouse sera were used as negative controls in the neutralization assays. Percent reduction 
in IFUs was determined as follows: 100  ￿  [(IFUs control sera -  IFUs experimental sera)/IFUs Control Sera]. 
" mAb A-20 contained 1 mg protein/ml before dilution. 
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A  VDI  (residues  61-85) 
Figure 1.  Fine  specificity  of the antibody response in A/J mice immunized 
with peptide A8-VDI. Pooled sera from A/J mice immunized with pep- 
tide AS-VDI were tested against sequential and overlapping octameric pep- 
tides corresponding  to the primary sequence of serovar A MOMP VDI 
(residues 61-85). Antibodies reacted strongly with six octameric peptides 
spanning VDI residues 69-81 (top), which included the serovar A-specific 
MOMP epitope ~IVAGLEK~6  recognized by the neutralizing  mAb A-20 
(bottom). The VAGLEK epitope recognized by mAb A-20 is denoted by 
the stippled pattern  in the VDI sequence. 
munogen but was not effective as secondary or booster im- 
munogeu (Table 2). Mice primed with peptide A8-VDI and 
then given a secondary immunization with 3  x  107 IFUs 
of serovar A EBs in IFA produced exceptionally high-titered 
antibodies to the VDI peptide and serovar A EBs. These sera 
also had higher titers of chlamydial-specific neutralizing an- 
tibodies. In contrast to these findings, peptide AS-VDI was 
not an effective secondary immunogen for the production 
of an anamnestic antibody response in mice that were primed 
with intact serovar A EBs. These findings suggest that the 
A8 Th cell epitope(s) may not be the immunodominant de- 
terminant in the context of intact chlamydial EBs. However, 
once T  cell pods specific to the A8 peptide have been in- 
duced, they are apparently preferentially expanded in response 
to secondary immunization with intact chlamydial  organisms. 
Immunogenicity of Peptide A8-VD1 in Inbred Mouse Strains 
Disparate at 1-1-2.  Th cell immunity is MHC restricted and 
it is generally accepted that in a given haplotype-specific Th 
cell stimulation is a necessary prerequisite to B cell prolifera- 
tion (27). To determine whether the Th cell epitopes con- 
rained in the A8 portion of peptide A8-VDI could be recog- 
nized by multiple MHC haplotypes, we studied its ability 
to induce an IgG antibody response specific to VDI in inbred 
strains of mice differing at H-2. As a control for T cell recog- 
nition of the A8 portion of the chimeric peptide, mice were 
also immunized with the VDI peptide alone. If an IgG anti- 
body response specific  to VDI was dependent on immuniza- 
tion with the chimeric peptide it was interpreted that the 
given H-2 haplotype was capable of recognizing the Th cell 
epitope contained in the A8 sequence. Six inbred strains of 
mice having different H-2 haplotypes were immunized with 
peptide A8-VDI or the VDI peptide alone and their sera tested 
for antibody reactivity to peptide VDI, MOMP, and EBs 
(Fig. 2). All inbred strains of mice immunized with the A8- 
VDI peptide produced IgG antibodies reactive with the VDI 
peptide. In contrast,  ouly C57BL/10  (H-2  b) mice produced 
anti-VDI antibodies after immunization with the free VDI 
peptide. These results indicate that multiple H-2 haplotypes 
recognize the Th cell epitope(s) contained in the A8 sequence. 
The ability of VDI alone to induce an IgG antibody response 
in C57BL/10 mice shows that in addition to B cell epitopes 
the VDI sequence also contains a Th ceU epitope(s) recog- 
nized by C57BL/10  mice. Although all the inbred strains 
of mice tested produced anti-VDI antibodies only some strains 
of mice produced antibodies reactive with the MOMP and 
intact chlamydial EBs (Fig. 2). A/J, CBA, and DBA mouse 
strains made antibodies that recognized the MOMP and in- 
tact EBs, but C57BL/10,  BALB/c, and SJL antisera either 
reacted weakly or not at all with these antigens. 
Neutralizing  Activity of Anti-AS-VDI Antibodies Produced 
in Different Inbred Mouse Strains.  Since some mouse strains 
produced antibodies reactive with the VDI peptide but not 
intact EBs, it was important to determine if these anti-VDI 
antibodies were capable of neutralizing chlamydial infectivity. 
The in vitro neutralizing activity of the anti-A8-VDI  sera 
from different inbred mice is shown in Table 3. A/J, DBA, 
and CBA mouse sera were neutralizing whereas C57BL/10, 
BALB/c, and SJL sera were nonneutralizing.  Therefore, al- 
though the AS-VDI peptide evoked  antibody responses against 
peptide VDI in each of the inbred mice tested, only certain 
strains produced functional neutralizing antibodies. The ability 
of mouse sera to neutralize infectivity correlated directly with 
its reactivity to intact EBs by ELISA. A possible explanation 
for these findings was that the fine specificity of the anti- 
bodies produced after immunization ofpeptide A8-VDI was 
different among the mouse strains. 
Fine S~cificity of  Anti-A8-VDl Antibodies Produced  in Different 
Inbred Mouse Strains.  Anti-A8-VDI sera from each mouse 
strain were assayed against overlapping octapeptides corre- 
sponding to the VDI sequence using the peptide-pin  assay 
(Fig. 3). Anti-A8-VDI mouse sera that were reactive with 
intact EBs that were neutralizing (A/J, DBA, and CBA) and 
recognized octapeptides spanning the serovar A-specific neu- 
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5 wk after primary  immunization  3 wk after secondary immunization 
ELISA antibody  ELISA antibody 
Immunogen  titer  titer 
Neutralizing  Neutralizing 
Primary  Secondary  VDI  EBs  titer (NDso)  VDI  EBs  titer (NDso) 
PBS  A EBs  <16  <16  ND  64  32  ND 
A8-VDI  PBS  4,096  4,096  512  4,096  4,096  1,024 
A8-VDI  A EBs  4,096  4,096  1,024  32,768  65,536  8,192 
PBS  A8-VDI  <16  <16  ND  128  128  ND 
A EBs  PBS  2,048  4,096  1,024  2,048  2,048  1,024 
A EBs  AS-VDI  1,024  4,096  2,048  4,096  4,096  2,048 
ELISA and neutralization titers are expressed as described in Table 1. Groups of five A/J mice were used for each experiment. Mice primed with 
peptide A8-VDI were injected intraperitoneally with 50 gg peptide in CFA. Mice boosted with peptide AS-VDI were immunized intraperitoneally 
with the same concentration of peptide emulsified  in IFA. Mice primed with EBs were immunized intraperitoneally with 3  x  107 IFUs in CFA. 
Mice boosted with EBs were immunized intraperitoneally with the same quantity of EBs in IFA (note that this quantity of EBs was subimmunogenic 
since it did not elicit a significant antibody response in mice when administered intraperitoneally in IFA). 
tralizing epitope VAGLEK. In contrast, those mouse sera that 
did not react with intact EBs by ELISA and that were non- 
neutralizing  (C57BL/10,  BALB/c, and SJL) failed to react 
with VDI octapeptides containing  the VAGLEK sequence, 
or had very low levels of reactive antibody against the epi- 
tope. The fact that peptide AS-VDI did not induce antibodies 
to the VAGLEK epitope in C57BL/10, BALB/c, and SJL mice 
provides an explanation for the lack of neutralizing  activity 
observed with these mouse sera (Table  3). 
It is unclear why those mouse sera which reacted with the 
VDI peptide by ELISA did not react with octameric pep- 
tides in the peptide-pin assay. It is possible that  these sera 
contain antibodies made against structural determinants  of 
the VDI peptide that are not present in octameric peptides 
or that they recognized linear epitopes in VDI that exceeded 
eight  amino  acid residues. 
Antibody Response of  H-2 Congenic Mouse Strains Immunized 
with Peptide  A8-VDI.  To further characterize  the genetic con- 
trol of the immune response to peptide A8, and to more pre- 
cisely ascertain if the differences in the molecular specificity 
of the antibody response observed in inbred strains of mice 
(Fig. 3) were associated with H-2 haplotype, we immunized 
groups of A and B10 H-2-congenic mouse strains with pep- 
tide A8-VDI. We chose these strains since A/J and C57BL/10 
mice represented responder and nonresponder strains,  respec- 
tively, to the VAGLEK-neutralizing epitope. A corresponding 
pattern of antibody responsiveness to the VDI peptide and 
intact EBs was also observed in these same strains  of con- 
genic mice (Fig. 4). All three A strain-congenic mice, A/J 
(H-2a),  A.BY  (H-2  b) and  A.SW  (H-2s), immunized  with 
the A8-VDI produced antibodies reactive with the VDI pep- 
tide and intact serovar A EBs. In contrast, B10-congenic strains 
of mice, C57BL/10 (H-2b), B10.A (H-2a), and B10.BR (H- 
2k), produced antibodies reactive with the VDI peptide, but 
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these antibodies did not react with  intact  EBs.  A.BY (H- 
2  b) mice immunized with VDI peptide alone produced an- 
tibody reactive with the VDI peptide and EBs, further demon- 
strating that the VDI sequence contains a Th cell epitope(s) 
whose immunogenicity  is H-2  b restricted. 
Discussion 
In previous studies we showed that peptide A8, which cor- 
responds to serovar A MOMP residues 106-130, contained 
a Th cell epitope(s) that  was capable of providing cognate 
T  cell  help  for  the  production  of antibody  to  a  serovar 
A-specific B cell epitope located in VDI (16). We colinearly 
synthesized A8 and VDI sequences as a chimeric T/B cell 
peptide, designated AS-VDI, and showed it to be highly im- 
munogenic in mice. Polyclonal antibodies produced in A/J 
mice against AS-VDI reacted only with the VDI portion of 
the chimera and recognized the VDI sequence in its native 
conformation on the surface of intact chlamydial EBs. These 
preliminary findings were encouraging with respect to the 
potential use of the chimeric peptide in the design of a syn- 
thetic chlamydial vaccine. However, they did not address other 
functional and immunogenic properties of the chimeric pep- 
tide that are important towards this end. Here, we have per- 
formed further studies to delineate the immunogenic prop- 
erties of this chimeric peptide to more thoroughly address 
its potential use in chlamydial vaccine development. We showed 
that antibodies produced to the chimeric T/B peptide were 
functional neutralizing  antibodies and that they recognized 
the same linear serovar A-specific MOMP epitope (VAGLEK) 
in the VDI sequence as a neutralizing serovar A-specific mAb. 
We demonstrated that  the chimeric peptide could function 
as an effective priming immunogen for the production of high- 
titered serum-neutralizing antibodies after secondary immu- A 
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Figure 2.  Immunogenicity  of peptide A8-VDI in inbred strains of mice 
having different H-2 haplotypes. Six different inbred strains of mice (five 
mice per group) were immunized with peptide A8-VDI (A) or VDI (B) 
alone. The mouse sera were tested by ELISA for IgG antibodies to peptide 
VDI, serovar A MOMP, and serovar A EBs. All six inbred strains of mice 
immunized with peptide A8-VDI produced significant IgG antibodies reac- 
tive with the VDI peptide. In contrast, immunization  with peptide VDI 
alone did not generate an IgG antibody response in five of the six different 
inbred strains of mice. The exception  was C57BL/10  (H-2  b) mice in 
which immunization  with peptide VDI alone produced antibodies reac- 
tive with peptide VDI. Although the six different inbred strains of mice 
produced anti-VDl antibodies, only strains A/J, DBA, and CBA produced 
antibodies reactive with the MOMP and intact EBs. 
nization with intact EBs. Lastly, we demonstrated that the 
chimeric T/B cell peptide was immunogenic  in mouse strains 
having different H-2 haplotypes suggesting that the Th cell 
epitope(s)  contained in the A8 portion of the chimera was 
recognized by multiple MHC haplotypes. 
An effective  trachoma vaccine will likely depend on boosting 
protective antibody responses to MOMP in immunized in- 
dividuals by either exposure to or reinfection by chlamydiae 
under natunl environmental conditions. This will require that 
the vaccine contain MOMP-derived Th cell epitope(s), and 
not alien or heterologous carrier molecules. Our data showed 
that peptide A8-VDI could function as an effective priming 
immunogen for the production of high-titered serum neu- 
tralizing antibodies after secondary challenge immunization 
with intact chlamydial EBs (Table 2). In contrast, the pep- 
tide did not function as an effective secondary immunogen 
for boosting serum-neutralizing antibody responses in mice 
that had been primed with intact EBs. A possible explana- 
tion for these findings is that primary immunization with 
peptide A8-VDI  selectively induced Th cell and B cell re- 
sponses to epitopes contained within this peptide. Upon sec- 
ondary immunization with intact EBs, these T  and B cell 
pools were preferentially  expanded resulting in the produc- 
tion of extremely high-titered neutralizing antibodies.  The 
inability of peptide A8-VDI to function as a boosting im- 
munogen in mice primed with intact EBs indicates that the 
A8 Th cell epitope(s) is a cryptic determinant that is not im- 
munodominant in the context of the native MOMP mole- 
cule. Despite its apparent cryptic nature in the context of 
native MOMP the A8 T cell determinant(s), when presented 
in a peptide form, is capable of binding multiple MHC mol- 
ecules and provides helper T cell function for the production 
of neutralizing antibody which can be boosted by immuni- 
zation with intact chlamydiae. These data suggest that the 
A8 peptide may contain suitable T  cell determinant(s) for 
the development of synthetic trachoma vaccine. 
Antigen-specific Th cell responses are MHC class II re- 
stricted (28, 29). In the context of vaccine design, immunogens 
possessing defined Th cell epitopes should be recognized by 
multiple H-2 alleles to be effective in a genetically diverse 
population. In attempts to delineate the H-2 restriction in 
the recognition of the Th cell epitope(s)  contained within 
the A-8 peptide, we studied the immunogenicity of peptide 
A8-VDI in mouse strains  of different H-2 haplotypes. We 
found that six inbred mouse strains immunized with peptide 
A8-VDI produced antibodies reactive with the VDI peptide 
indicating that Th cell epitope(s) contained in the A8 pep- 
tide are recognized by multiple H-2 haplotypes. A disturbing 
aspect of these studies was that the fine specificity of the an- 
tibody response to VDI varied among mouse strains. Although 
all mouse strains tested produced antibodies reactive with the 
VDI peptide, only certain strains produced antibodies that 
reacted with intact EBs and recognized the neutralizing epi- 
tope VAGLEK in the VDI sequence (Figs. 2 and 3). It is not 
understood why different mouse strains produced antibodies 
with different molecular specificities  to the VDI peptide. Three 
H-2-congenic A strain mice made antibodies reactive with 
intact EBs whereas three H-2-congenic B10 mice did not pro- 
duce antibodies reactive with EBs. Thus, the differences in 
antibody-fine specificity to the VDI peptide produced by 
different mouse strains are likely not H-2 related but are per- 
haps due to differences in other, possibly Ig genes, that con- 
trol the production of antibody to VDI. The inability of some 
mouse strains to respond to the VAGLEK epitope might be 
explained by a hole in their B cell repertoire that renders them 
incapable of responding to this epitope. Alternatively, the epi- 
tope might not be properly presented by some strains of mice 
during antigen processing. 
The VDI peptide alone was immunogenic in C57BL/10 
and A.BY mice, indicating that the VDI sequence contains 
both Th cell and B cell epitopes.  This result is perhaps not 
unexpected since the VDI peptide contains two predicted 
Rothbard (30)  T  cell motif sequences  (residues  7~ 
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Figure 3.  Fine specificity of the antibody response in 
inbred strains of mice immunized with peptide A8-VDI. 
Mouse sera were tested at a 1:100 dilution against sequen- 
tial overlapping octameric peptides corresponding to the 
VDI sequence. A/J, CBA, and DBA mice produced anti- 
bodies  reactive with  VDI-octameric  peptides  whereas 
C57BL/10, BALB/c,  and SJL mouse sera were negative 
or reacted very weakly with VDI octapeprides. A/J and 
DBA mice produce antibodies reactive with the VAGLEK- 
neutralizing epitope whereas CBA mice recognized octa- 
meric peptides COOH terminal to this epitope. The fine 
specifidty of the antibody response among inbred strains 
of mice correlates with antibody-neutralizing activity. For 
example, A/J and DBA mouse sera contained antibodies 
reactive with the VAGLEK  epitope and were neutralizing. 
In contrast, mouse sera that were nonreactive with VDI 
octameric peptides or failed to produce antibodies to the 
VAGLEK sequence were non-neutralizing. The VAGLEK 
recognized by mAb A-20 is denoted by the stippled pattern. 
and ZrDPVANSt) and an amphipathic c~-hdix segment (31) 
(residues 76KDPVANVAR s4) with an amphipathic score of 
15.1.  Our findings that MOMP VDs contain Th cell epi- 
topes confirm the findings of Allen et al. (32) who have local- 
ized T  cell determinants to MOMP VDs.  The Th cell epi- 
topes  contained  in  MOMP  VDs  may  not  however  be 
particularly attractive  for the development  of a chlamydial 
vaccine.  For example,  as we have  shown here,  the Th cell 
epitope(s) in the serovar A  MOMP VDI  sequence is H-2  b 
restricted.  In addition, the MOMP VDs represent hypervari- 
Table  3.  Neutralizing Properties of Anti-A8-VDI Sera 
Produced in Inbred Mice of Different H-2 Haplotypes 
Mouse  H-2  ELISA  Neutralizing 
strain  haplotype  anti-EB  titer  titer (NDs0) 
A/J  a  16,384  4,096 
C57BL/10  b  <16  <16 
BALB/c  d  <16  <16 
CBA  k  128  32 
DBA/1  q  1,024  256 
SJL  s  <16  <16 
ELISA and neutralization  titers are expressed as the reciprocal of serum 
dilutions resulting in OD (405 nm) of 0.3 or a 50% reduction in chlamydi- 
al IFUs,  respectively. 
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Figure 4.  Immunogenicity of peptide A8-VDI in congenic mouse strains 
differing at H-2. Congenic A and B10 mouse strains differing at H-2 were 
immunized with peptide A8-VDI (A) and VDI (B),  their sera tested by 
ELISA against VDI and serovar A  EBs. Pepfide A8-VDI was immuno- 
genic in H-2 congenic A and B10 mouse strains. Congenic A mouse strains 
produced antibodies reactive with both the VDI peptide and intact serovar 
A EBs whereas B10-congenic mice made antibodies that reacted only with 
the peptide VDI. The VDI peptide alone was immunogenic in C57BL/10 
(H-2  b) and A.BY (H-2  b) mice demonstrating  that the VDI peptide con- 
rains a Th cell epitope(s) in addition to B cell epitopes and that this epi- 
tope is H-2  b restricted. Thus, the differences observed in antibody  fine 
specificity to VDI epitopes among different mouse strains are not H-2 
linked but are more likely due to differences in immunoglobulin genes 
among the different mouse strains. able sequences among different C. trachomatis  MOMP genes 
(13, 14) indicating that the T cell-antigenic determinants that 
map to these regions are likely to be antigenically unique 
among different C.  trachomatis  MOMPs. 
The  A8  sequence  is  highly conserved among different 
C.  trachomatis  MOMP genes indicating that its Th cell epi- 
tope(s)  is antigenically common among different MOMPs. 
Our findings indicate that the Th cell determinant(s) in the 
A8 sequence is capable  of priming Th cell immunity that 
can be recalled by native EBs. Moreover, multiple H-2 haplo- 
types recognize the A8 Th cell epitope(s).  Collectively, these 
properties are encouraging in respect  to the potential use of 
the A8 peptide in the design of a synthetic trachoma vaccine. 
We are currently investigating the immunogenicity  of  colinear 
peptides corresponding to the A8 sequence in association with 
trachoma B and C serovar-specific neutralizing epitopes. The- 
oretically, a trivalent vaccine consisting of synthetic peptides 
or recombinant proteins comprised of the A8 sequence  in 
combination with these linear B cell-neutralizing epitopes 
may be effective in producing protective neutralizing anti- 
bodies against all three trachoma serovars. 
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